Last edition
News about "life sciences investors"
Ambros Therapeutics Launches with USD 125 Million Series A to Advance CRPS Therapy
Ambros Therapeutics has launched with a USD 125 million Series A financing to advance neridronate for Complex Regional Pain Syndrome Type 1, supported by multiple FDA designations and an oversubscribed round led by RA Capital Management and Patient Square Capital, with a pivotal phase III trial planned for early 2026.
Life Sciences Investors | 19/12/2025 | By News Bureau | 390
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members